Cytovance Biologics Inc. Announces New Hire In R&D

Learn more at www.Cytovance.com

Cytovance Biologics, Inc. is pleased to announce the appointment of Seth Fisher as Director of Purification Development in the R&D Services group. Mr. Fisher, a Boston University Trustee Scholar, has over 20 years' experience in research, process development, scale-up and manufacture of complex biologics for both east and west coast biotech companies, including large pharma and contract biomanufacturing.
"We are very excited to have Seth join the R&D Services team here in Oklahoma City. His broad training in biologics research, downstream process development and scale-up as well as customer facing experiences are a great fit for navigating the complexities of the clinical programs we see in the CMO space," said Jesse McCool, Senior Vice President of R&D Services. "Seth has some great ideas for expanding our capabilities and business footprint informed by his professional experiences across some of the industry's leading companies."

As a trained protein biochemist, Seth focused most of his career on supporting discovery pipelines working on the purification of proteins for several clinical areas including cancer, autoimmune diseases, inflammatory diseases and infectious diseases. His industry experience includes technical hands-on, supervisory and SME positions at AMGEN (Thousand Oaks), GSK (SmithKline Beecham Pharmaceuticals), Peregrine Pharmaceuticals, and Avid/Stamford Bioprocessing. A decade of experience at AMGEN exposed him to the challenges of parallel programming where he gained practical experiences in monoclonal antibodies, peptides and Fc-peptide fusions, enzymes, cytokines, kinases, antiangiogenic factors and vaccine proteins. His work at AMGEN included extensive refolding process development of E. coli derived inclusion bodies and the subsequent development of downstream processes. At GSK, he was involved in the discovery of a novel kinase p38 and a HIV protease as well as the process development, scale-up and production of Phase I drug substance. More recently, he directed the development, optimization and transfer of numerous downstream processes to clinical manufacturing while serving as the chromatography SME at Avid Manufacturing. Early in his career as a research scientist at the University of Pennsylvania, he isolated phospholipase C, kinases and phosphatases for elucidation of the IP3 signaling pathway. 


MEDIA CONTACT
Cheryl Tuck
Marketing Communications Manager
Email Contact
405.319.8310

Suggested Articles

The takeover centers on a near-approval anti-CGRP antibody that could address Lundbeck’s need for near-term revenue drivers.

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.